Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update Jul 28, 2021
Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome Jul 7, 2021
Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference Jul 1, 2021
ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES Jun 29, 2021
Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock Jun 25, 2021
Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference Nov 19, 2020
Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A Open-Label Trial of Ibezapolstat for Treatment of C. difficile Infection (CDI) Nov 5, 2020
Acurx Actively Enrolling Patients in Ph2 Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) Jul 23, 2020
Acurx Receives USAN Approval of Non-proprietary Name Ibezapolstat for Its Phase 2 Novel, First-in-Class Antibiotic for C. difficile Infection Jan 15, 2020
